Clinical trial NCT00705003: Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)
Official title: A Double-Blind, Placebo-Controlled Study of a Combination Product (BCI-024 and BCI-049) in Patients With Major Depressive Disorder (MDD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Major Depressive Disorder
Keywords: depression
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: BrainCells Inc.
First posted: 2008-06-25
Enrollment: 142
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study are to evaluate the synergistic effect of a combination product, consisting of drug BCI-024 (buspirone) and drug BCI-049 (melatonin), in reducing symptoms of depression in patients with Major Depressive Disorder.

The safety and tolerability of the combination product will also be evaluated as measured by adverse events and vital signs.

Detailed description: Approximately 120 adult outpatients meeting the study's inclusion and exclusion criteria will be randomized in the study.

Eligibility criteria: Inclusion Criteria:

* Subjects will be male and female subjects between the ages of 18 to 65 meeting the Diagnostic and Statistical Manual of Mental Disorders-IV-Text Revision (DSM-IV-TR) criteria for Major Depressive Disorder with a Quick Inventory of Depressive Symptomatology-16 Item Self Report (QIDS-SR16) score of \>14 at the Screening and Baseline Visits.
* Female subjects must be on a stable and medically reliable form of birth control, must agree to continue use of this birth control during the study, and must have negative urine pregnancy tests at the Screening Visit.

Exclusion Criteria:

* Subjects with any other psychiatric Axis-I disorder as a principal diagnosis within 6 months of screening or subjects with a history of obsessive compulsive disorder, psychotic disorder, bipolar disorder, or mental retardation at any time are not eligible for the study.
* Subjects who pose a suicidal risk or who have a history of eating disorder or substance dependence within 6 months of screening, or a history of substance abuse within 3 months of screening are also ineligible.
* Subjects with clinically significant abnormalities on any Screening or Baseline assessments, including laboratory tests, are excluded.
* Subjects with a known intolerance to either buspirone or melatonin are excluded, as are subjects with clinically significant medical or psychiatric conditions that might be detrimental to the subject should they participate in the study.
* Subjects who have used selective serotonin reuptake inhibitors (SSRIs) within 2 weeks of Screening (within 4 weeks for fluoxetine) are excluded as are subjects requiring concomitant use of antipsychotic and anxiolytic medications and any drugs with known psychotropic properties. Concomitant medications that are not excluded by the protocol and that are taken chronically must be at a stable dosage for at least 4 weeks prior to screening.

Primary outcomes:
measure: The Score on the Clinical Global Impression-Improvement (CGI-I) at Week 6
timeFrame: Week 6
Secondary outcomes:
measure: The Change From Baseline in the CGI-S at Week 6
timeFrame: Baseline and Week 6
measure: The Change From Baseline in the IDS-C30 at Week 6
timeFrame: Week 0 and Week 6
measure: The Change From Baseline in the Quick Inventory of Depressive Symptomatology - 16 Item Self-Report (QIDS-SR16) at Week 6
timeFrame: Baseline and Week 6
measure: The Change From Baseline on the HAM-A at Week 6
timeFrame: Week 0 and Week 6
Other outcomes:
Locations:
city: Garden Grove
country: United States
facility: Collaborative Neuroscience Network, Inc.
state: California
city: San Diego
country: United States
facility: Synergy Research Centers
state: California
city: Altanta
country: United States
facility: Atlanta Institute of Medicine & Research, Inc.
state: Georgia
city: Rockville
country: United States
facility: Capital Clinical Research Associates
state: Maryland
city: Beachwood
country: United States
facility: NorthCoast Clinical Trials
state: Ohio
city: Philadelphia
country: United States
facility: CRI Worldwide
state: Pennsylvania
city: Austin
country: United States
facility: FutureSearch Clinical Trials, L.P.
state: Texas
city: Dallas
country: United States
facility: FutureSearch Trials of Dallas, L.P.
state: Texas
city: Houston
country: United States
facility: Claghorn-Lesem Research Clinic, Ltd.
state: Texas
Study officials:
affiliation: Massachusetts General Hospital
name: Maurizio Fava, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Massachusetts General Hospital
name: Andrew A Nierenberg, MD
role: PRINCIPAL_INVESTIGATOR
References: